Introduction {#s1}
============

Hepatorenal syndrome (HRS) is a reversible cause of renal impairment that occurs in patients with cirrhotic ascites, as well as in patients with alcoholic hepatitis or acute liver failure who show no significant abnormalities in the kidneys morphology ([@B8]; [@B16]; [@B7]).

HRS is characterized by marked alterations in cardiovascular function, impaired renal function, and over-activity of renin-angiotensin systems that lead to severe renal vasoconstriction with a significant reduction of the glomerular filtration rate (GFR) as well as vigorous activation of the sympathetic nervous system ([@B8]; [@B16]).

HRS predicts mortality in cirrhosis. The most important aspect of providing care to patients with HRS is an evaluation of candidacy for orthotopic liver transplantation ([@B24]; [@B29]; [@B40]). Current accessible therapies other than liver transplantation for HRS consist of albumin and the utilization of vasoconstrictors, for example, terlipressin ([@B6]).

Recently, only 52% of HRS patients have responded to therapy with terlipressin ([@B32]; [@B18]; [@B23]; [@B2]). Furthermore, few researches have reported some predictors of response to treatment in HRS patients treated with this regimen.

The endothelium release many vasoactive mediators that change the structure and function of the vascular smooth muscle in response to mechanical and humoral stimuli. Two of the most prominent are ET and NO ([@B12]). ET-1 is released in response to infectious complications with an inflammatory response in the form of transcription mediators activation and proinflammatory cytokines (IL-1, IL-6, and TNF-α) production. It also plays an important role in the vascular disruption pathogenesis caused by infection ([@B15]; [@B52]; [@B20]).

The pathophysiology of various disorders is closely related on the ET-1/NO imbalance ([@B3]). In cirrhosis and HRS, the ET system dysfunction causes hemodynamic disturbances ([@B36]; [@B51]).

The identification of patients with low therapeutic response probability is of imperative clinical importance, especially in patients waiting for transplantation. In our study, we evaluated the hypothesized predictors of response to albumin and terlipressin in type-1 HRS and cirrhosis patients treated with this protocol.

Patients and Methods {#s2}
====================

Study Population {#s2_1}
----------------

Starting 2015, patients with renal impairment and cirrhosis admitted to the Tropical Medicine Department (Mansoura, Egypt) were assessed using the same diagnostic algorithm ([@B22]), that involves evaluation of the possible causes of hypovolemia, diuretic withdrawal, possible infection, drug nephrotoxicity, and renal parenchymal disorders. To exclude the presence of volume depletion related renal failure, plasma expansion with I.V. albumin was tried. According to the International Ascites Club ([@B8]), patients who met the type-1 HRS criteria, were treated with albumin and terlipressin. The new HRS defining criteria were approved by this study protocol ([@B7]). Some patients didn\'t receive therapy due to having advanced hepatocellular carcinoma, severe cardiovascular disorders and/or being terminal cases (death expected in less than 2 days).

All the differential diagnosis causes of cirrhotic acute kidney injury including: organic (including glomerulonephritis and acute tubular necrosis), prerenal (all accessible hypovolemic causes), and obstructive nephropathy ([@B21]; [@B33]) were excluded in this study by meticulous history taking and physical examination, together with complete biochemical analysis and radiological investigations.

The existence of infection was assessed by various methods, for example, culture and sensitivity testing for ascitic fluid, blood, sputum, and urine, evaluation of the ascitic fluid absolute polymorphonuclear (PMN) count, and chest radiography. Patients with infection were precluded from this study and received albumin and terlipressin only when renal failure continued after the infection was successfully treated. According to the type of infection, bacterial infections were initially treated with antibiotics as reported in detail elsewhere ([@B34]; [@B19]). The antibiotic was changed according to the results of the cultures if there was no response to the initial therapy. In patients with negative cultures and not responding to the initial therapy, empiric antibiotics policy consisting of vancomycin and carbapenems combination was used ([@B10]).

The current study included 42 consecutive cirrhosis/type-1 HRS patients who were subjected to treatment from March 2015 to February 2019. Twenty nine (69%) of them had bacterial infection induced type-1 HRS including 20 SBP cases, six soft tissue infection cases, and three patients with pneumonia as well as 13 patients with HRS without known risk factors.

Bacterial infections were categorized according to the following criteria: SBP is the presence of an ascitic ﬂuid absolute polymorphonuclear count \>250/mm^3^ and/or a positive ascitic fluid bacterial culture with no apparent source of infection ([@B46]); spontaneous bacteremia is positive blood cultures without an evident source of infection; local infections (skin infection, urinary tract infection, pneumonia, gastroenteritis, meningitis, and biliary tract infection) were evaluated utilizing standard criteria; sepsis with negative-culture is leukocytosis with/without band forms, the presence of fever (\>38°C), together with negative cultures, after the exclusion of disorders other than infection that could be related to the systemic inﬂammatory response.

Improvement of SBP was deﬁned as a reduction in polymorphonuclear cell count \<250/mm^3^, absence of clinical signs of infection, negative cultures, and normal leukocyte count. The remaining infections were improved according to the conventional criteria. Septic shock was identified as a mean arterial pressure below 60 mmHg regardless of adequate volume resuscitation and need for vasopressor agents ([@B17]).

In this study, all specific therapy or treatment was delayed for type-1 HRS until the infection has been cured.

In addition, the control group included 42 cirrhotic patients without renal impairment who were sex- and age-matched subjects (male/female = 27/15).

Treatment Protocol {#s2_2}
------------------

The response to treatment was considered a primary endpoint, determined by either a decline in serum creatinine level \>50% of the pretreatment value, or \>1.5 mg/dL during treatment with an end-of-therapy level of ≤1.5 mg/dL.

Terlipressin (Glypressin, Ferring S.A., Saint-Prex, Switzerland) was administrated as follows; 0.5--1 mg/4 h, as intravenous (i.v.) bolus for 3 days with an increase up to 2 mg/4 h for those whose values did not decrease by at least 25% of the pretreatment values. The maximum duration of therapy was 2 weeks. Once serum creatinine is reduced below 1.5 mg/dL, Terlipressin was withheld. If patients developed manifestations matching the ischemic complications, administration of Terlipressin was stopped.

All patients received albumin (Baxter Human Albumin 20%, Baxter AG, Industriestraße 67, A-1221 Vienna, Austria) at a dose of 1 g/kg BW. during the first day, followed by 40 g/d, given for a maximum of 15 days, in order to reach the inferior vena cava collapsibility index (*IVCCI*) ≥40% and ≤75%. Clinically, *IVCCI* was evaluated daily in a regular manner throughout the follow-up period. The dose of albumin was decreased to 20 g/d and/or was stopped if *IVCCI* was \<40% ([@B11]). All measurements were carried out by qualified ultrasound radiologists. Moreover, if radiological and clinical signs of pulmonary edema developed, the administration of albumin was withheld, and the patients received i.v. doses of furosemide with careful follow-up.

During therapy of HRS, any complications of cirrhosis were treated based on standardized therapeutic measures ([@B14]).

Sampling {#s2_3}
--------

Following an overnight fasting of 12 h, 4 to 8 mL blood *were withdrawn* through cannulas in superficial forearm *veins* for all patients \[1 mL in EDTA for complete blood count (CBC), 5mL without anticoagulants for serum samples\].

Methodology {#s2_4}
-----------

CBC was assessed using the CELL-DYN Emerald cell counter (Abbott, Wiesbaden, Germany). Serum creatinine, blood urea nitrogen (BUN) and liver function tests were measured on a Dimension Xpand plus chemistry analyzer (Siemens Technology, Princeton, NJ, USA) using commercially available enzyme-based kit and reagents. Quantitative detection of plasma nitric oxide (NO) was measured using ELISA kits provided by MyBiosource (San Diego, CA 92195-3308, USA) Cat No. MBS264607, with detection range 1.56 to 100 nmol/mL (nmol/mL = µmol/L). Though the NO role in various disorders is debatable, the majority of researchers agree that evaluating serum levels of NOx are associated with NO production. ([@B5]). Quantitative detection of plasma Endothelin-1 (ET-1) was measured using ELISA kits provided by MyBiosource (San Diego, CA 92195-3308, USA) Cat No. MBS025621, with detection range 6.25 to 200 pg/mL (pg/mL = ng/L). Plasma L-Arginine was quantitatively measured using ELISA kits provided by ALPCO (26G Keewaydin Drive, Salem, New Hampshire 3079, United States) Cat No. 30-7733, with detection range 12.5 to 300 µmol/L. The estimated glomerular filtration rate (eGFR) was calculated according to the following formula ([@B31]): 186 x (Creatinine/88.4)^-1.154^ x (Age)^-0.203^ x (0.742 if female) x (1.210 if black). The ET-1/NO ratio was calculated and recorded for all patients.

Ethics {#s2_5}
------

The protocol of this study was completed to acclimate with the Declaration of Helsinki and was affirmed by the Ethics Committee of the Mansoura University. Informed consent was obtained from all enrolled patients or their legal representatives.

Statistical Analysis {#s2_6}
--------------------

The analysis was carried out using SPSS version 20 for Windows (SPSS Inc., Chicago, IL). Results are expressed as the mean ± SD. Comparisons of continuous and categorical variables between patients were carried out using Student *t*- and *X* ^2^-tests respectively. A paired Wilcoxon test and Student *t*-test were used to compare the variables measured at various time points. The multivariate analysis was built using the univariate analysis parameters that had a significant predictive value (*P* \< 0.01). The best cutoff values for variables with independent predictive value were measured using receiver operating characteristic curves. The probability of response was evaluated using the Kaplan--Meier method. The calculation of overall response involved patients who received a liver transplant (n = 3) and the results were viewed redacted at the time of transplantation. *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Patient Characteristics {#s3_1}
-----------------------

Only 42 out of the 121 patients with cirrhotic ascites and renal failure were included in this study. The etiology of renal failure was evaluated after admission and HRS was diagnosed following the diagnostic criteria reported by Angeli et al. Of all the excluded patients, 51 were due to previous infection exposure who were discharged from hospital with normal renal function after adequate therapy of infection (32 SBP, 12 soft tissue infections and 7 pneumonia), six due to nephrotoxic agents administration (four aminoglycosides and two contrast agents), seven due to hypovolemic causes (five GIT bleeding and two severe vomiting), and three due to obstructive nephropathy. Also, the 12 patients who showed complete response and marked serum creatinine decline after receiving only albumin as a corrective measure for the pre-renal causes of renal failure were excluded.

Baseline characteristics of patients with type-1 HRS at the time of diagnosis before starting the treatment with albumin and terlipressin are reported in [**Table 1**](#T1){ref-type="table"}. Not surprisingly, most patients with type-1 HRS had severe liver failure, as demonstrated by increased international normalized ratio (INR), high Model for End-Stage Liver Disease (MELD) and Child-Pugh scores, low estimated GFR using Modification of Diet in Renal Disease equation, high levels of serum bilirubin, creatinine, L-arginine, NOx, serum ET-1, and ET-1/NO ratio *compared* to the control group.

###### 

Baseline characteristics of patients with type-1 hepatorenal syndrome at the time of diagnosis.

  -------------------------------------------------------------------------------------------------------------
  Parameters                         Cirrhotic patients with HRS\   Cirrhotic patients without HRS\   *P*
                                     (n = 42)                       (control group)\                  
                                                                    (n = 42)                          
  ---------------------------------- ------------------------------ --------------------------------- ---------
  Age (years)                        45 ± 9                         44 ± 8.7                          0.61

  Sex (male/female)                  29/13                          27/15                             0.889

  BMI (kg/m^2^)                      27 ± 5.9                       26.5 ± 5.4                        0.686

  Etiology of liver cirrhosis                                                                         

   CHB-related liver cirrhosis       39 (92.8)                      37 (88.1)                         0.466

   CHB-related liver cirrhosis       2 (4.8)                        3 (7.2)                           0.645

   NASH-related liver cirrhosis      1 (2.4)                        2 (4.7)                           0.571

  Hematocrit (%)                     28 ± 7                         30 ± 8.5                          0.243

  WBCs (×10^3^/mm^3^)                4.7 ± 2.4                      4.5 ± 2.1                         0.686

  Platelet count (×10^3^/mm^3^)      95 ± 74                        102 ± 69                          0.655

  AST (U/L)                          60 ± 32                        56 ± 27                           0.538

  ALT (U/L)                          55 ± 27                        50 ± 24                           0.372

  T. Bilirubin (mg/dL)               10.8 ± 8.3                     1.9 ± 1.2                         \<0.001

  Serum albumin (g/dL)               2.6 ± 0.6                      2.5 ± 0.7                         0.484

  INR                                2.2 ± 0.6                      1.8 ± 0.5                         0.001

  Serum creatinine (mg/dL)           2.8 ± 1.4                      1.1 ± 0.4                         \<0.001

  eGFR (mL/min/1.73 m^2^)            57 ± 2.9                       74 ± 9.3                          \<0.001

  BUN (mg/dL)                        38.4 ± 8.4                     37.7 ± 7.9                        0.695

  Urine volume (mL/d)                585 ± 279                      968 ± 453                         \<0.001

  Na (mmol/L)                        129 ± 7                        130 ± 11                          0.621

  K (mmol/L)                         4.12 ± 0.7                     4.23 ± 0.8                        0.504

  Child-Pugh score                   11+1.5                         9.75+1.3                          \<0.001

  MELD score                         28 ± 9                         22+10                             0.005

  L-arginine (μmol/L)                92.5 ± 15.3                    74.5 ± 10.2                       \<0.001

  Oxide metabolites (NOx) (μmol/L)   70.6 ± 3.9                     49.5 ± 1.1                        \<0.001

  Endothelin-1 (ET-1) (ng/L)         29.1 ± 1.9                     13.3 ± 0.9                        \<0.001

  ET-1/NO ratio                      0.42 ± 0.036                   0.27 ± 0.02                       \<0.001
  -------------------------------------------------------------------------------------------------------------

BMI, basal metabolic index; CHB, chronic hepatitis B; CHC, chronic hepatitis C; eGFR, estimated glomerular filtration rate; MELD score, Model for End-Stage Liver Disease score; NASH, nonalcoholic steatohepatitis; WBCs, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; Na, sodium; K, potassium; ET-1/NO ratio, endothelin-1/nitric oxide ratio.

Predictive Factors For Treatment Response {#s3_2}
-----------------------------------------

Twenty out of the 42 patients (48%) had a response to therapy. Generally, at the end of therapy, serum creatinine decreased below 1.5 mg/dL, while in two patients serum creatinine decreased \>50% of the pretreatment levels but stayed above 1.5 mg/dL (4.8 decreased to 1.8 mg/dL and 3.7 to 1.7 mg/dL). The rest of the patients (52%) failed to reach the response to therapy criteria. Serum creatinine levels during the therapy period in non-responders and responders are summarized in [**Figure 1**](#f1){ref-type="fig"}. During therapy, the probability of response in all patients is shown in [**Figure 2**](#f2){ref-type="fig"}. The estimated period for response was approximately 2 weeks. Response to therapy was merely constant in most patients. Recurrence of HRS was 4/20 (20%) in patients who responded to therapy. The average period for recurrence was 2 weeks (range, 3--38 days).

![Changes in serum creatinine concentration during treatment in responders and nonresponders.](fphar-11-00009-g001){#f1}

![Probability of response to treatment in patients with type 1 HRS treated with albumin and terlipressin. Dotted lines represent 95% confidence intervals. The numbers under the curve are patients at risk at each time.](fphar-11-00009-g002){#f2}

At baseline, several parameters obtained were assessed for the predictive value of response to therapy ([**Table 2**](#T2){ref-type="table"}). Parameters related to response to therapy (*P* \< 0.05) were WBCs count, AST level, serum bilirubin level, urine volume, and MELD score. Furthermore, neither ET-1/NO ratio nor serum creatinine level at baseline was related to response to treatment. The only parameter found to have an independent predictive value in the multivariate analysis was the serum bilirubin level (OR, 14.2; 95% CI, 1.256--160.77; *P* = 0.032). By receiver operating characteristic curves, serum bilirubin level has a cutoff value (\< 8 mg/dL) that well-predicted response to therapy, (AUC = 0.751; *P* \< 0.001; specificity = 55%; sensitivity = 85%; PPV = 63%; and NPV = 80%). Response rates in patients classified based on baseline serum bilirubin level \<8 or ≥8 mg/dL were 63% (17/27) and 20% (3/15), respectively (*P* = 0.008).

###### 

Univariate analysis of baseline parameters according to response to treatment with albumin and terlipressin.

  -----------------------------------------------------------------------------
  Parameters                         Responders\    Non-responders\   *P*
                                     (n = 20)       (n = 22)          
  ---------------------------------- -------------- ----------------- ---------
  Age (y)                            44 ± 10        43 ± 8            0.72

  Sex (male/female)                  14/6           15/7              0.97

  BMI (kg/m^2^)                      25 ± 5.2       27 ± 6.1          0.26

  Etiology of liver cirrhosis                                         

   CHC-related liver cirrhosis       19 (95)        20 (91)           0.62

   CHB-related liver cirrhosis       1 (5)          1 (4.5)           0.94

   NASH-related liver cirrhosis      \-             1 (4.5)           \-

  Hematocrit (%)                     27 ± 6         29 ± 8            0.37

  WBCs (×10^3^/mm^3^)                4.1 ± 2.2      5.8 ± 2.7         0.03

  Platelet count (×10^3^/mm^3^)      108 ± 85       91 ± 69           0.48

  AST (U/L)                          49 ± 27        69 ± 34           0.04

  ALT (U/L)                          48 ± 23        63 ± 31           0.08

  T. bilirubin (mg/dL)               5.5 ± 1.8      15.5 ± 9          \<0.001

  Serum albumin (g/dL)               2.5 ± 0.7      2.6 ± 0.8         0.67

  INR                                1.9 ± 0.6      1.8 ± 0.5         0.56

  Serum creatinine (mg/dL)           2.3 ± 1.4      2.9 ± 1.6         0.21

  eGFR (mL/min/1.73 m^2^)            58 ± 2.5       56 ± 2.7          0.02

  BUN (mg/dL)                        38 ± 8.2       38.7 ± 8.8        0.792

  Urine volume (mL/d)                475 ± 125      395 ± 90          0.02

  Na (mmol/L)                        129 ± 9        126 ± 7           0.23

  K (mmol/L)                         4 ± 0.9        4.11 ± 1          0.71

  Child-Pugh score                   11 ± 1         12 ± 2            0.051

  MELD score                         20 ± 6         25 ± 9            0.04

  L-arginine (μmol/L)                89.4 ± 12.4    84.5 ± 11.3       0.19

  Oxide metabolites (NOx) (μmol/L)   72 ± 2.8       69.5 ± 4.9        0.052

  Endothelin-1 (ET-1) (ng/L)         29.7 ± 1.2     30.5 ± 1.4        0.055

  ET-1/NO ratio                      0.43 ± 0.016   0.44 ± 0.028      0.169
  -----------------------------------------------------------------------------

BMI, basal metabolic index; CHB, chronic hepatitis B; CHC, chronic hepatitis C; eGFR, estimated glomerular filtration rate; MELD score, Model for End-Stage Liver Disease score; NASH, nonalcoholic steatohepatitis; WBCs, white blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; Na, sodium; K, potassium; ET-1/NO ratio, endothelin-1/nitric oxide ratio.

Based on changes in the ET-1/NO ratio evaluated at day 3 of therapy, we analyzed response rates in all patients. The value of the ET-1/NO ratio used was the average value of all measurements of ET-1/NO ratio assessed at day 3; a reduction in ET-1/NO ratio of 0.15 was considered relevant and used as a cutoff value. Values of ET-1/NO ratio throughout therapy in non-responders and responders are summarized in [**Figure 3**](#f3){ref-type="fig"}. Although the baseline ET-1/NO ratio was not a predictive factor of response, early changes of ET-1/NO ratio within the first days of therapy predicted response. Patients with a reduction in the ET-1/NO ratio equal to or greater than 0.15 at day 3 of therapy had a response rate at the end of treatment of 85% (17/20) compared to 13.6% (3/22) in patients with minimal decreases in the ET-1/NO ratio (*P* \< 0.001). When this decrease in the ET-1/NO ratio of 0.15 or more at day 3 was enclosed in the multivariate analysis with the baseline parameters, the predictive factors of response to treatment were the baseline serum bilirubin level and the decrease in the ET-1/NO ratio ≥0.15 at day 3 ([**Table 3**](#T3){ref-type="table"}). Moreover, 2/5 patients (40%) responded if there was a reduction ET-1/NO ratio ≥0.15 in those with baseline serum bilirubin level ≥8 mg/dL, compared to a response in 1/10 (10%) in those with a change in the ET-1/NO ratio \<0.15 with baseline serum bilirubin level ≥8 mg/dL ([**Figure 4**](#f4){ref-type="fig"}).

![Changes in ET-1/NO ratio during treatment in responders and nonresponders.](fphar-11-00009-g003){#f3}

###### 

Parameters with independent predictive value of response to treatment with albumin and terlipressin in patients with type 1 HRS.

  Parameters                                 Univariate analysis   Multivariate analysis                                     
  ------------------------------------------ --------------------- ----------------------- ---------- ------ --------------- ----------
  Baseline serum bilirubin                   6.8                   1.54--30.8              0.012      14.2   1.256--160.77   0.032
  ∆ ET-1/NO ratio at day 3 ≥1.5              35.9                  6.37--202.2             \< 0.001   59.3   5.98--586.92    \< 0.001
  ∆ Serum creatinine at day 3 \> 0.5 mg/dL   5.0                   1.35--18.6              \< 0.001   9.46   0.84--105.9     0.048

CI, confidence interval; OR, odds ratio; ET-1/NO ratio, endothelin-1/nitric oxide ratio.

![Response rate according to levels of ET-1/NO ratio and its relationship to serum bilirubin at baseline.](fphar-11-00009-g004){#f4}

In addition, Spearman\'s correlation analysis showed that there was a significant correlation between the ET-1/NO ratio and serum bilirubin level, serum creatinine level, creatinine clearance, MELD and Child-Pugh scores (*rho* = 0.63, *P* \< 0.001; *rho* = 0.72, *P* \< 0.001; *rho* = −0.66, *P* \< 0.001; *rho* = 0.72, *P* \< 0.001; *rho* = 0.69, *P* \< 0.001respectively).

During therapy, the early decrease in serum creatinine was also used as a predictor of response to treatment. Response to therapy was demonstrated in 15 of the 19 patients (79%) in whom serum creatinine decreased by at least 0.5 mg/dL at day 3, compared to only 5 of the 23 patients (22%) in whom serum creatinine did not decrease 0.5 mg/dL or elevated at day 3 compared to the baseline (*P* \< 0.001). When the cutoff value for the change in serum creatinine used was 1 mg/dL instead of 0.5 mg/dL similar figures were demonstrated (89% and 36%, respectively; *P* = 0.005). The value of the reduction in serum creatinine at day 3 as a predictor of response to treatment was also approved in the multivariate analysis model (odds ratio, 9.46; *P* = 0.048).

Complications of Cirrhosis {#s3_3}
--------------------------

A total of 47 major cirrhotic complications were developed in 37 patients (88%) during therapy: 32 patients with hepatic encephalopathy, five patients with GIT bleeding, and ten patients with bacterial infection. Bacterial infections between responders and non-responders showed no signiﬁcant difference \[4/20 (20%) vs. 6/22 (27%), respectively; *P* = 0.6\]. The median value for WBCs count was 7,100/mm^3^ and throughout therapy, the occurrence of bacterial infections was partially more common in patients higher count than in those with lower count \[7/23 (30.4%) vs. 3/19 (15.8%), respectively; *P* = 0.275\]. At the lower WBCs count baseline, patients acquired pneumonia (n = 1) and urinary tract infections (n = 2) after an average period of 6 days (range, 2--10 days), while at the higher WBCs count baseline, patients acquired pneumonia (n = 2) and sepsis (n = 5) after an average period of 6 days (range, 2--14 days).

Side Effects of Therapy {#s3_4}
-----------------------

Eight patients (19%) developed albumin/terlipressin therapy-related side effects. Signs of circulatory overload developed in four patients, that improved after short-lived cessation of albumin but not of terlipressin and furosemide was added in small doses. Intestinal ischemia signs developed in two patients, that disappeared after cessation of therapy. Transient arrhythmia (ventricular extrasystolia) developed in two patients, that did not need persistent cessation of therapy, and improved after therapy withdrawal. We followed up with the patients for at least 3 months after their hospital discharge.

Survival {#s3_5}
--------

90 days after the initiation of treatment, 32 (76.2%) patients died, 6 (14.3%) patients were still alive, 3 (7.2%) participants had undergone liver transplantation, and 1 (2.4%) patient was lost to follow-up as well as the survival probability at that time was significantly higher in responders (40%) with median survival of 65 days compared to non-responders (9%) with median survival of 8 days; *P* \< 0.001). Septic shock (n = 16), multiorgan failure (n = 11), liver failure (n = 4), and/or unknown (n = 1) were the *causes of death.*

Using the original MELD risk equation, Area Under the Receiver Operating Characteristic Curve (AUROC) analysis revealed that a MELD score threshold of 20 corresponded to median survival less than 3-months ([**Figure 5**](#f5){ref-type="fig"}). Kaplan-Meier survival curves of patients stratified by baseline MELD score below or above 20, which represents threshold for 3-month median survival. Median survival of patients with baseline MELD score \<20 significantly greater than those with baseline MELD scores ≥ 20 (62 vs. 15 days, *P* \< 0.001).

![Kaplan-Meier survival curves of patients stratified by baseline MELD score below or above 20, which represents threshold for 3-month median survival. Median survival of patients with baseline MELD score \<20 significantly greater than those with baseline MELD scores ≥ 20 (62 vs. 15 days, *P* \< 0.001).](fphar-11-00009-g005){#f5}

Discussion {#s4}
==========

This recent study reports that albumin with terlipressin are currently the accepted therapy for type-1 HRS, but over 50% of patients show a suboptimal to no response to treatment ([@B16]; [@B7]). It is therefore of paramount importance that we keep searching and investigating not only for adequate predictors of response but also prognostic factors before beginning the treatment or early afterward. Obviously, patients responding to treatment showed a statistically significant decline in ET-1/NO ratio at the end of therapy; probably because the low effective arterial blood volume of HRS was improved. These outcomes firmly recommend that the gainful impact of terlipressin in the treatment of HRS is identified with its ability to enhance systemic hemodynamics ([@B18]; [@B38]). We still don\'t know why in some type-1 HRS patients the systemic hemodynamics were not enhanced when treated with terlipressin. This may be due to the presence of concomitant adrenal insufficiency, and latent infections associated with higher levels of ET-1 ([@B26]).

Independent predictors of response to treatment were serum bilirubin levels at baseline and a decline in the ET-1/NO ratio ≥0.15 at day 3 of therapy. Eleven of the eleven patients (100%) with serum bilirubin at baseline \<8 mg/dL who demonstrated a decline in the ET-1/NO ratio ≥0.15 at day 3 responded to our therapeutic protocol. While only one of the 10 (10%) patients with serum bilirubin at baseline ≥8 mg/dL and a reduction in the ET-1/NO ratio \<0.15 had a response to therapy. In previous studies, predictive variables of response observed in patients with HRS involved MELD and Child-Pugh scores, arterial pressure, and serum creatinine level at the baseline ([@B39]; [@B1]; [@B42]; [@B48]; [@B49]). But some drawbacks may be observed as a small number of patients received therapy as well as analysis may have involved patients treated with different vasoconstrictors e.g. norepinephrine instead of terlipressin.

The association between the renal response to terlipressin and the presence of an early reduction of the ET-1/NO ratio shows the significance of the enhancement of systemic hemodynamics in accomplishing type-1 HRS reversal. ET-1 and NO are the most important local vasoconstrictor and vasodilator respectively. They seem to play a role in almost every tissue and organ ([@B25]). Recent researches reported that the important factors in identifying the harmful versus beneficial effects of NO are the site of NO production, duration of action, and its amount ([@B27]). It has been proposed that the disequilibrium of ET-1 and NO levels may have an impact on the pathophysiology of local and systemic circulation disorders. This imbalance in the renal microcirculation has been proposed to be in charge of the dynamic disintegration in kidney function in these patients and the development of HRS ([@B30]).

ET-1 may be involved in both impaired glomerular perfusion and renal vasoconstriction which causes HRS ([@B37]). Renal blood flow is not the only factor contributing to changes in glomerular filtration rate as seen at the microcirculatory level. The enhanced production of vasoactive mediators including ET-1 causes reduction of the surface area available for glomerular filtration and contraction of mesangial cells which contributes to this phenomenon ([@B47]; [@B50]). The intake of ETA and ETB receptors antagonists combination prevented and in sometimes reversed the pathogenesis of renal failure in different experiments ([@B4]). Physiologically, early reduction of the ET-1/NO ratio is considered a good prognostic marker in HRS patients with end stage liver disease or on the liver transplantation waiting list.

Interestingly, serum bilirubin level at baseline was considered an independent predictive factor of response to treatment. Poor response to therapy and elevated serum bilirubin levels association can\'t be explained, but looks to be unrelated to the hemodynamic response to terlipressin. The mechanisms explaining the lack of response to terlipressin related to high serum bilirubin levels are interesting and merits examination. The correlation between the ET-1/NO ratio and bilirubin noticed in this study demonstrates that the values of ET-1 are influenced by the excretory liver function. A correlation between ET-1 and bilirubin has been approved also by some ([@B43]; [@B9]), but not all authors ([@B28]). The possible explanation, not determined by our data, maybe owing to indirect (excess pulmonary *arteriovenous* shunts that increased with the deterioration of liver condition) and direct (reduced clearance of ET-1 by the hepatic tissue) associations. Leakage of bile into the blood and/or disturbance of ET-1 degradation may result in increased serum ET-1 levels since ET-1 is excreted through the biliary system ([@B13]).

The multivariate analysis model showed that the reduction in serum creatinine level at day 3 can be considered a predictor of response to treatment. It should be noted that up to one-fourth of the patients showed response at the end of therapy though their serum creatinine level was not reduced by day 3. This may be due to increasing the dose of terlipressin in patients whom their serum creatinine level failed to reach an early reduction or showed a delayed renal response with respect to the improvement of hemodynamic status. In these patients, treatment with terlipressin was maintained after 3 days to achieve this delayed response effect. This finding is approved by [@B41].

In the current study, the 90-day survival probability in non-responders was 9% and in responders 40%. These results, in conjunction with the observation that patients with HRS where the albumin and terlipressin enhanced their renal capacity had marvelous posttransplantation results compared to patients without HRS ([@B45]), confirm that albumin plus terlipressin is a successful and helpful choice for HRS patients anticipating liver transplantation. The observations of this study were in accordance with previous reports which stated that type-1 HRS patients responding to therapy with albumin and terlipressin have longer survival expectancy compared to that of non-responders \[([@B44]; [@B35]; [@B42]; [@B49]).

Moreover, to our knowledge, no studies published the role of changes in the ET-1/NO ratio as an independent predictor of response to albumin with terlipressin in type-1 HRS. Such results will certainly be much scrutinized, but there are some clear conclusions for the role of ET-1 and NO in the pathophysiology of HRS. Such findings add to our understanding and knowledge of the pathogenesis of HRS in a number of ways and provide a foundation for its management. This study\'s findings have a number of significant implications for future practice.

Of course, this study has some limitations that should be addressed. First, the sample size is small. Second, the current study is a single center study, and recruiting a large number of patients for such a meticulous study, is mandatory yet difficult due to the unavailability of terlipressin in many centers and type-1 HRS is not a common disorder. Third, the ET-1/NO ratio is not routinely measured in clinical practice. Furthermore, studies from multiple centers are needed to confirm these findings in HRS patients.

In conclusion, the outcomes of the current study, in type-1 HRS patients, indicate that a reduction in the ET-1/NO ratio and lower serum bilirubin baseline are considered good predictors of response to treatment with albumin and terlipressin. Future studies on treatment of type-1 HRS should discuss the possible mechanisms of declined response to pharmacological treatment and should search for new therapeutic options for non-responders.
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